Athira Pharma Inc - Asset Resilience Ratio
Athira Pharma Inc (ATHA) has an Asset Resilience Ratio of 20.68% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Athira Pharma Inc total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Athira Pharma Inc's Asset Resilience Ratio has changed over time. See ATHA net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Athira Pharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Athira Pharma Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $19.05 Million | 20.68% |
| Total Liquid Assets | $19.05 Million | 20.68% |
Asset Resilience Insights
- Good Liquidity Position: Athira Pharma Inc maintains a healthy 20.68% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Athira Pharma Inc Industry Peers by Asset Resilience Ratio
Compare Athira Pharma Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Athira Pharma Inc (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Athira Pharma Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 20.68% | $19.05 Million | $92.15 Million | +15.85pp |
| 2024-12-31 | 4.83% | $2.84 Million | $58.78 Million | -30.64pp |
| 2023-12-31 | 35.47% | $56.84 Million | $160.25 Million | -4.97pp |
| 2022-12-31 | 40.43% | $104.38 Million | $258.15 Million | -2.71pp |
| 2021-12-31 | 43.14% | $143.22 Million | $332.01 Million | -1.24pp |
| 2020-12-31 | 44.38% | $124.06 Million | $279.56 Million | -- |
| 2019-12-31 | 0.00% | $0.00 | $2.19 Million | -- |
| 2018-12-31 | 30.41% | $1.50 Million | $4.93 Million | -- |
About Athira Pharma Inc
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds… Read more